<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="editorial" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medsovet</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский Совет</journal-title><trans-title-group xml:lang="en"><trans-title>Meditsinskiy sovet = Medical Council</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2079-701X</issn><issn pub-type="epub">2658-5790</issn><publisher><publisher-name>REMEDIUM GROUP Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21518/2079-701X-2018-10-56-62</article-id><article-id custom-type="elpub" pub-id-type="custom">medsovet-2533</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Химиотерапия злокачественных опухолей</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Malignant tumor chemotherapy</subject></subj-group></article-categories><title-group><article-title>Цитотоксическая терапия: от прошлого к будущему</article-title><trans-title-group xml:lang="en"><trans-title>Cytotoxic therapy: from past to future</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>редакционная</surname><given-names>статья</given-names></name><name name-style="western" xml:lang="en"><surname>Editotial</surname><given-names>Article</given-names></name></name-alternatives></contrib></contrib-group><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>18</day><month>07</month><year>2018</year></pub-date><volume>0</volume><issue>10</issue><fpage>56</fpage><lpage>62</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; редакционная с., 2018</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="ru">редакционная с.</copyright-holder><copyright-holder xml:lang="en">editotial a.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.med-sovet.pro/jour/article/view/2533">https://www.med-sovet.pro/jour/article/view/2533</self-uri><abstract><p>Одним из событий XXI Российского онкологического конгресса (Москва, 14–16 ноября 2017 г.) стал симпозиум «Место цитотоксической терапии в XXI веке», организованный компанией «Верофарм». Ведущие российские онкологи обсудили позиции химиотерапии на современном этапе, практические аспекты и перспективы использования цитостатиков в противоопухолевой терапии.</p><p>В работе симпозиума приняли участие:</p><p>Материал подготовила Людмила Головина</p></abstract><trans-abstract xml:lang="en"><p>The symposium «The Role of Cytotoxic Therapy in the 21st Century» held by Veropharm was one of the events of the 21nd Russian Cancer Congress (Moscow, November 14–16, 2017). The leading Russian oncologists discussed the role of chemotherapy at the current stage, practical aspects and prospects for using cytostatics in the antitumor therapy. </p></trans-abstract></article-meta></front><back><ref-list><title>References</title></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
